Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA finds 'multiple problems' with Ampligen data; Hemispherx gets whacked

This article was originally published in Scrip

Executive Summary

Shares of Hemispherx Biopharma plummeted 51% on 18 December after US FDA drug reviewers said there were “multiple problems” with the company's data submitted in its new drug application (NDA) for Ampligen (rintatolimod), an investigational treatment intended for use in patients with chronic fatigue syndrome (CFS), a complex, debilitating disorder of unknown etiology.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC019810

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel